反応式
[CH:1]1[N:9]([C@@H:10]2[O:14][C@H:13]([CH2:15][O:16][P:17]([OH:20])([OH:19])=[O:18])[C@@H:12]([OH:21])[C@@H:11]2[OH:22])[C:8]2[C:3](=[C:4]([NH2:24])[N:5]=[C:6]([F:23])[N:7]=2)[N:2]=1.[O-2].[Mg+2:26]>O>[CH:1]1[N:9]([C@@H:10]2[O:14][C@H:13]([CH2:15][OH:16])[C@@H:12]([OH:21])[C@@H:11]2[OH:22])[C:8]2[C:3](=[C:4]([NH2:24])[N:5]=[C:6]([F:23])[N:7]=2)[N:2]=1.[Mg+2:26].[P:17]([O-:20])([O-:19])([O-:18])=[O:16].[P:17]([O-:20])([O-:19])([O-:18])=[O:16].[Mg+2:26].[Mg+2:26]参加物
4
実験手順
10.0 g of fludarabine phosphate at a purity of 97.5% is suspended in 100 ml of water within about 5 minutes, and magnesium oxide is added to this solution. The mixture is stirred for one more hour at room temperature and then filtered. The clear solution is poured into 200 ml of acetone, stirred for 1 more hour, and the crystallizate is separated by filtration. 10.0 g (95% of theory) of the fludarabine-phosphate magnesium salt is obtained.
後処理
- filtrationfiltered
- additionThe clear solution is poured into 200 ml of acetone
- stirringstirred for 1 more hour
- customthe crystallizate is separated by filtration
出典と根拠
- ORDレコード
- ord-51090bcb15194d508c3c7e0872bdadfc
- 出典データセット
- uspto-grants-2000_04
- 特許番号
- US06046322
関連ノート
読み込み中…